Stockscreener 앱 받기
68.12
0.56%
0.38
시장 영업 전:
68.80
0.68
+1.00%
전일 마감가:
$67.74
열려 있는:
$67.48
하루 거래량:
2.78M
Relative Volume:
1.13
시가총액:
$13.32B
수익:
$579.96M
순이익/손실:
$-729.89M
주가수익비율:
-18.19
EPS:
-3.7459
순현금흐름:
$-452.02M
1주 성능:
+2.61%
1개월 성능:
+3.67%
6개월 성능:
-4.95%
1년 성능:
+26.59%
1일 변동 폭
$0.00
$0.00
1주일 범위
$66.72
$69.32
52주 변동 폭
$52.75
$93.42
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
68.12 | 13.32B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-03 | 개시 | Canaccord Genuity | Buy |
| 2026-05-26 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2026-05-19 | 개시 | Citigroup | Neutral |
| 2026-04-09 | 개시 | RBC Capital Mkts | Outperform |
| 2026-03-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics - Yahoo Finance
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
32 new hires get awards tied to 57,853 shares, but vesting depends on continued employment. - Stock Titan
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records - GlobeNewswire Inc.
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 - GlobeNewswire Inc.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares - Investing.com
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares By Investing.com - Investing.com Nigeria
BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan - Stock Titan
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans - AD HOC NEWS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120 - Moomoo
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Nigeria
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Canada
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BBIO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
BridgeBio Pharma: Attruby Peak Sales Set To Rise - Seeking Alpha
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com Canada
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
BridgeBio at Wells Fargo conference: growth plan centers on 2027 launches - Investing.com India
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
BBIO: Multiple late-stage therapies targeting rare genetic diseases set for US launches by 2027 - TradingView
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain - Benzinga
BridgeBio reports Phase 3 infigratinib achondroplasia data - grafa.com
BridgeBio Oncology Therapeutics, Inc. SEC Filing (Sep 9, 2026) - stocktitan.net
13 Red Days In A Row: BridgeBio Pharma Stock Is Down 11% - Trefis
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Nigeria
BBIO Looks 51.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Canada
BridgeBio’s infigratinib shows improvements in achondroplasia study - investing.com
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
BridgeBio Pharma Reports Favorable Exploratory PROPEL 3 Data for Oral Infigratinib in Achondroplasia, Including Sleep Apnea and Ear Infection Trends - Quiver Quantitative
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KUMAR HALDEA FAMILY IRREVOCABL | Director |
Aug 19 '26 |
Proposed Sale |
82.98 |
30,000 |
2,489,400 |
0 |
| Kumar Neil | Chief Executive Officer |
Aug 19 '26 |
Sale |
84.03 |
10,000 |
840,257 |
505,686 |
| Kumar Neil | Chief Executive Officer |
Aug 18 '26 |
Sale |
82.53 |
34,980 |
2,886,994 |
243,327 |
| NEIL KUMAR | Director |
Aug 18 '26 |
Proposed Sale |
79.89 |
34,980 |
2,794,552 |
0 |
| RANDAL SCOTT | Director |
Aug 17 '26 |
Proposed Sale |
79.86 |
21,501 |
1,717,070 |
0 |
| Apuli Maricel | Chief Accounting Officer |
Jul 30 '26 |
Sale |
80.06 |
2,000 |
160,120 |
127,401 |
| Ellis Andrea | Director |
Jul 09 '26 |
Option Exercise |
16.75 |
17,167 |
287,547 |
39,746 |
| ANDREA ELLIS | Director |
Jul 09 '26 |
Proposed Sale |
84.00 |
17,167 |
1,442,028 |
0 |
| JENNIFER COOK | Director |
Jul 09 '26 |
Proposed Sale |
88.54 |
148,589 |
13,156,008 |
0 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Sale |
88.54 |
148,589 |
13,156,008 |
8,383 |
1.26%
0.23%
자본화:
|
볼륨(24시간):